Frenki Gjika, MPH* and Emily Fehderau, MPH

University of Edinburgh, United Kingdom

*Corresponding Author: Frenki Gjika, MPH, University of Edinburgh, United Kingdom.

Received: March 19, 2023; Published: May 05, 2023

Abstract

Barriers to communicable disease control are widespread and varying throughout the world. The COVID-19 pandemic has made poignant the need to understand and correct existing and emerging barriers to suppressing the spread infectious diseases. This paper describes the barriers faced by China and its surrounding countries that led to the global public health crisis. Critically appraising barriers on the levels of agent, case, population and system informs where public health efforts failed and how they may be rectified. As countries continue to grapple with the effects of the virus’ spread, evaluating barriers faced early in the outbreak provide lessons for ongoing optimization of control measures for novel infectious agents.

Keywords: Early Barriers; Disease Control; COVID-19

References

1. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet 395 (2020): 497-506.
2. Wu JT., et al. “Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China”. Nature Medicine (2020b): 1-5.
3. Hua J and Shaw R. “Corona virus (Covid-19) “infodemic” and emerging issues through a data lens: The case of china”. International Journal of Environmental Research and Public Health 17 (2020): 2309.
4. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 51 (2020b).
5. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 106 (2020c).
6. Shi Y., et al. “COVID-19 infection: the perspectives on immune responses”. Nature Publishing Group (2020).
7. Guan W-J., et al. “Clinical characteristics of coronavirus disease 2019 in China”. New England Journal of Medicine 382 (2020): 1708-1720.
8. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China”. JAMA 323 (2020b): 1061-1069.
9. Yang J., et al. “Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study”. The Lancet Infectious Diseases (2020).
10. Shereen MA., et al. “COVID-19 infection: origin, transmission, and characteristics of human coronaviruses”. Journal of Advanced Research (2020).
11. Webster RG. “Wet markets--a continuing source of severe acute respiratory syndrome and influenza?” The Lancet 363 (2004): 234-236.
12. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 1 (2020a).
13. Wu D., et al. “The SARS-CoV-2 outbreak: What we know”. International Journal of Infectious Diseases 94 (2020a): 44-48.
14. Wang CJ., et al. “Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing”. JAMA 323 (2020a): 1341-1342.
15. Tsang TK., et al. “Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study”. The Lancet Public Health (2020).
16. Bai HX., et al. “Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT”. Radiology (2020): 200823.
17. Lippi G and Plebani M. “The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks”. Clinical Chemistry and Laboratory Medicine (CCLM) 1 (2020).
18. Shim E., et al. “Transmission potential and severity of COVID-19 in South Korea”. International Journal of Infectious Diseases (2020).
19. Wu Z and Mcgoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. JAMA 323 (2020): 1239-1242.
20. Hu Z., et al. “Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China”. Science China Life Sciences (2020): 1-6.
21. Villa S., et al. “The COVID-19 pandemic preparedness or lack thereof: from China to Italy”. Global Health and Medicine (2020).
22. Mizumoto K., et al. “Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020”. Eurosurveillance 25 (2020): 2000180.
23. Emanuel EH., et al. “Fair allocation of scarce medical resources in the time of Covid-19”. Massachusetts Medical Society (2020).
24. Oh J., et al. “National Response to COVID-19 in the Republic of Korea and Lessons Learned for Other Countries”. Health Systems and Reform 6 (2020): e-1753464.

Citation

Citation: Frenki Gjika and Emily Fehderau. “Exploring the Early Barriers to Disease Control for COVID-19 in China" Acta Scientific Neurology 6.6 (2023): 08-12.

Copyright

Copyright: © 2023 Frenki Gjika and Emily Fehderau. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.